SEC Form 8-K: Press Release dated June 3, 2024

BPTH_20240602_8-K

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

BPTH-ASCO_Data_Press_Release

SEC Form 8-K: Press Release dated May 23 & May 24, 2024

BPTH_20240530_8-K

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

BPTH_EHA_Announcement_Release

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

BPTH_ASCO_Announcemen_2024

SEC Form 8-K: Press Release May 15, 2024

BPTH-Form_8-K_Q1-2024_Earnings_Release

SEC Form 10-Q for Period ending March 31, 2024

BPTH-Form_10-Q_Q1_2024

Bio-Path Holdings Reports First Quarter 2024 Financial Results

BPTH_First_Quarter_2024_Earnings_Announcement-1

BPTH_First_Quarter_2024-Earnings_Release

Webcast link to First Quarter 2024 Financial Results Conference Call – Wednesday, May 15, 2023 at 8:30 a.m. ET

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

BPTH_First_Quarter_2024_Earnings_Announcement